Synergy of endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and ERAP2) polymorphisms in atopic dermatitis: Effects on disease prevalence
Wanda Niepiekło-Miniewska(Ludwik Hirszfeld Institute of Immunology and Experimental Therapy), Piotr Kuśnierczyk(Immungenetics (Germany)), Izabela Nowak(Ludwik Hirszfeld Institute of Immunology and Experimental Therapy), Andrzej Wiśniewski(Ludwik Hirszfeld Institute of Immunology and Experimental Therapy), Karolina Piekarska(Ludwik Hirszfeld Institute of Immunology and Experimental Therapy), Aleksandra Lesiak(Medical University of Lodz), Piotr Kuna(Medical University of Lodz), Joanna Narbutt(ENT and Allergy), Łukasz Matusiak(Wrocław University of Science and Technology)
Cited by 5
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
|Journal of the European Academy of Dermatology and Venereology|2015|1.1k
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
|Journal of Allergy and Clinical Immunology|2012|642
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Hidradenitis suppurativa
|Nature Reviews Disease Primers|2020|567